China is rapidly emerging as a global leader in biopharma innovation, driving Asia’s share of the global biopharma pipeline to an impressive 43% by 2025, according to a McKinsey report. The country now commands 30% of the global innovative drug pipeline, a significant leap from its previous position as a “fast follower” in the industry.
The report highlights that China has been a major contributor to the 85% surge in global growth of innovative drug pipelines in 2024. Upfront payments for China-originated out-licensing deals surged from under $100 million in 2020 to over $800 million in 2024, showcasing China’s increasing influence in global biopharma.
The country’s biopharma sector is growing at an unprecedented pace. Clinical trials in China are 50% to 70% faster than the global average, with trials being two to five times quicker than those in the U.S. and European Union. This rapid pace is driven by China’s Centre for Drug Evaluation, which has significantly cut drug approval timelines, reducing the average from 4.5 years in 2018 to approximately one year in 2023.
China’s biopharma companies secured $26 billion in private equity and venture capital, with more than 80 companies launching IPOs through the Hong Kong Stock Exchange. The government has also invested heavily in biotech, establishing 12 innovation hubs and providing targeted public funding to support the sector’s growth.
China’s leadership extends to advanced areas such as antibody-drug conjugates, multispecific antibodies, protein degraders, RNA therapies, and radioligands, making it a formidable player in the global biopharma landscape, second only to the U.S. The country is also making strides in leading clinical trials, including first-in-China tests of new drug combinations.
